<- Go Home

Bavarian Nordic A/S

Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV, that is in phase 2 trial for the treatment of encephalitis viruses. It operates in the United States, Denmark, Canada, France, Germany, Singapore, England, Finland, Switzerland, Japan, Austria, Italy, Spain, Taiwan, Saudi Arabia, Australia, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

Market Cap

DKK 14.6B

Volume

357.0K

Cash and Equivalents

DKK 692.9M

EBITDA

DKK 1.4B

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

DKK 2.9B

Profit Margin

48.11%

52 Week High

DKK 244.80

52 Week Low

DKK 166.70

Dividend

N/A

Price / Book Value

1.16

Price / Earnings

12.84

Price / Tangible Book Value

2.16

Enterprise Value

DKK 12.4B

Enterprise Value / EBITDA

8.70

Operating Income

DKK 769.1M

Return on Equity

9.68%

Return on Assets

3.48

Cash and Short Term Investments

DKK 2.3B

Debt

DKK 139.3M

Equity

DKK 12.7B

Revenue

DKK 6.0B

Unlevered FCF

-DKK 501.8M

Sector

Biotechnology

Category

N/A

Company Stock Pitches